Theravance Biopharma Inc Asset Resilience Ratio
Theravance Biopharma Inc asset resilience ratio. Theravance Biopharma Inc (0TB) has an Asset Resilience Ratio of 37.29% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 0TB defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Theravance Biopharma Inc (2014–2024)
Asset resilience ratio of Theravance Biopharma Inc from 2014 to 2024. This chart shows how Theravance Biopharma Inc's Asset Resilience Ratio has changed over time. Read Theravance Biopharma Inc total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Theravance Biopharma Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 0TB total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €154.91 Million | 37.29% |
| Total Liquid Assets | €154.91 Million | 37.29% |
Asset Resilience Insights
- Very High Liquidity: Theravance Biopharma Inc maintains exceptional liquid asset reserves at 37.29% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Theravance Biopharma Inc Industry Peers by Asset Resilience Ratio
Compare Theravance Biopharma Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Theravance Biopharma Inc Asset Resilience Ratio by Year (2014–2024)
Theravance Biopharma Inc asset resilience ratio by year from 2014 to 2024. The table below shows the annual Asset Resilience Ratio data for Theravance Biopharma Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 14.27% | €50.55 Million ≈ $59.10 Million |
€354.16 Million ≈ $414.05 Million |
-2.19pp |
| 2023-12-31 | 16.46% | €62.88 Million ≈ $73.51 Million |
€382.00 Million ≈ $446.60 Million |
+11.64pp |
| 2022-12-31 | 4.83% | €29.31 Million ≈ $34.27 Million |
€607.40 Million ≈ $710.11 Million |
-17.45pp |
| 2021-12-31 | 22.28% | €83.51 Million ≈ $97.63 Million |
€374.82 Million ≈ $438.20 Million |
-22.81pp |
| 2020-12-31 | 45.08% | €211.47 Million ≈ $247.24 Million |
€469.06 Million ≈ $548.38 Million |
-9.40pp |
| 2019-12-31 | 54.49% | €222.77 Million ≈ $260.44 Million |
€408.83 Million ≈ $477.96 Million |
+31.77pp |
| 2018-12-31 | 22.71% | €127.25 Million ≈ $148.77 Million |
€560.24 Million ≈ $654.97 Million |
-36.10pp |
| 2017-12-31 | 58.81% | €259.59 Million ≈ $303.48 Million |
€441.40 Million ≈ $516.04 Million |
+34.35pp |
| 2016-12-31 | 24.46% | €156.39 Million ≈ $182.83 Million |
€639.25 Million ≈ $747.36 Million |
+4.56pp |
| 2015-12-31 | 19.90% | €59.73 Million ≈ $69.83 Million |
€300.12 Million ≈ $350.87 Million |
-29.07pp |
| 2014-12-31 | 48.97% | €165.40 Million ≈ $193.37 Million |
€337.77 Million ≈ $394.89 Million |
-- |
About Theravance Biopharma Inc
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). Its late-stage investigational once-daily norepinephrine reuptake inhibitor, Ampreloxetine is in the development for symptomatic neurogeni… Read more